NCT05384743

Rituximab Monotherapy for EBV-HLH and CAEBV

Rituximab Monotherapy for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection With Only and Mainly B Lymphocytes of EBV Infection

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Beijing Friendship Hospital · Academic / Other
• Sex: All
• Age: 2 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective single-arm clinical study, focusing on Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection with only and mainly B lymphocytes of EBV infection, to evaluate the clinical efficacy of Rituximab in the treatment of EBV-HLH and CAEBV.

Conditions

• Secondary Hemophagocytic Lymphohistiocytosis
• Chronic Active Epstein-Barr Virus Infection

Interventions

Type	Name	Description
DRUG	Rituximab Monotherapy	Rituximab 375mg/m2. This regimen was repeated after 1 week. A total of 2-4 courses of treatment.（After two courses of treatment, EBV-DNA turned negative, no need to apply again. If EBV-DNA is still positive after two courses of treatment, 2 courses of treatment are applied again).

Timeline

• Start date: 2022-02-01
• Primary completion: 2024-02-01
• Completion: 2024-04-01
• First posted: 2022-05-20
• Last updated: 2022-05-20

Locations

1 site across 1 country: China